Compare Hasbro, Inc. (HAS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Repligen Corporation Common Stock — how do they compare? Hasbro, Inc. trades at $96.15 (market cap $13.53B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Hasbro, Inc. is the larger of the two by market cap, and Hasbro, Inc. pays a 2.92% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Repligen Corporation Common Stock for 0 Days on average.
| HAS | RGEN | |
|---|---|---|
Market Cap | $13.53B | $11.14B |
Volume | 1,762,034 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $194.57 |
52-Week Low | $74.13 | $102.87 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $15.72B | $11.02B |
Dividend Yield | 2.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $95.46, up 0.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings beats in recent quarters (Q4 2025-Q2 2026) and positive cash flow trends, though 2025 net income was negative. Valuation metrics include a P/E of 17.07 and P/S of 2.74, while institutional interest remains high with recent purchases by HSBC and Virginia Retirement Systems.
Outlook is positive with a consensus price target of $107.60 (13% upside), supported by Magic: The Gathering growth and cost savings. Risks include high debt levels (debt-to-asset ratio of 59.09% in 2025) and sensitivity to consumer spending trends. The upcoming Q3 2026 earnings on October 20 will be a key catalyst.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
